Case report demonstrates fatal disease progression from a novel NOTCH1 fusion in a pediatric lymphoma patient, highlighting truncated NOTCH1 as a high-risk biomarker and therapeutic target.
T-cell lymphoblastic lymphoma (T-LBL) is an aggressive malignancy that comprises 20% of pediatric non-Hodgkin lymphoma cases. Most T-LBLs harbor NOTCH1 point mutations or small indels, which are generally associated with favorable outcomes. In contrast, the clinical impact of structural rearrangements involving NOTCH1 remains poorly understood. We describe the case of a 6-year-old boy with T-LBL carrying a MIR142HG::NOTCH1 fusion from a t(9;17)(q34;q23) translocation, resulting in a truncated, constitutively active NOTCH1 protein. The patient experienced an aggressive course and died shortly after cord blood transplantation. Literature review suggests that 9q34 translocations in T-LBL portend poor prognosis, highlighting truncated NOTCH1 as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Yamamori et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: